Association between the PPP3CC gene, coding for the calcineurin gamma catalytic subunit, and bipolar disorder by Mathieu, Flavie et al.
BioMed  Central
Page 1 of 4
(page number not for citation purposes)
Behavioral and Brain Functions
Open Access Short paper
Association between the PPP3CC gene, coding for the calcineurin 
gamma catalytic subunit, and bipolar disorder
Flavie Mathieu†1,2, Stéphanie Miot†1, Bruno Etain1,2, Marie-Anne El Khoury1, 
Fabien Chevalier1, Frank Bellivier1,2, Marion Leboyer1,2, Bruno Giros1 and 
Eleni T Tzavara*1,2
Address: 1INSERM U-513, Faculté de Médecine, 8 rue de Général Sarrail, 94000, Créteil, France and 2AP-HP, Albert Chenevier and Henri Mondor 
Hospitals, Department of Psychiatry, 94000, Créteil, France
Email: Flavie Mathieu - flavie.mathieu@creteil.inserm.fr; Stéphanie Miot - stephaniemiot@yahoo.fr; 
Bruno Etain - bruno.etain@creteil.inserm.fr; Marie-Anne El Khoury - marie-anne.elkhoury@snv.jussieu.fr; 
Fabien Chevalier - chevalier@creteil.inserm.fr; Frank Bellivier - frank.bellivier@creteil.inserm.fr; 
Marion Leboyer - marion.leboyer@creteil.inserm.fr; Bruno Giros - bruno.giros@snv.jussieu.fr; Eleni T Tzavara* - eleni.tzavara@creteil.inserm.fr
* Corresponding author    †Equal contributors
Abstract
Background:  Calcineurin is a neuron-enriched phosphatase that regulates synaptic plasticity and
neuronal adaptation. Activation of calcineurin, overall, antagonizes the effects of the cyclic AMP activated
protein/kinase A. Thus, kinase/phosphatase dynamic balance seems to be critical for transition to long-
term cellular responses in neurons, and disruption of this equilibrium should induce behavioral
impairments in animal models. Genetic animal models, as well as post-mortem studies in humans have
implicated calcineurin dependent calcium and cyclic AMP regulated phosphorylation/dephosphorylation in
both affective responses and psychosis. Recently, genetic association between schizophrenia and genetic
variation of the human calcineurin A gamma subunit gene (PPP3CC) has been reported.
Methods: Based on the assumption of the common underlying genetic factor in schizophrenia and bipolar
affective disorder (BPAD), we performed association analysis of CC33 and CCS3 polymorphisms of the
PPP3CC gene reported to be associated with schizophrenia in a French sample of 115 BPAD patients and
97 healthy controls.
Results: Carrying 'CT' or 'TT' genotypes of the PPP3CC-CC33 polymorphism increased risk to develop
BPAD comparing to carry 'CC' genotype (OR = 1.8 [1.01–3.0]; p = 0.05). For the PPP3CC-CCS3
polymorphism, 'AG' or 'GG' carriers have an increased risk to develop BPAD than 'AA' carriers (OR =
2.8 [1.5–5.2]). The CC33 and CCS3 polymorphisms were observed in significant linkage disequilibrium (D'
= 0.91, r2 = 0.72). Haplotype frequencies were significantly different in BPAD patients than in controls (p
= 0.03), with a significant over-transmission of the 'TG' haplotype in BPAD patients (p = 0.001).
Conclusion:
We suggest that the PPP3CC gene might be a susceptibility gene for BPAD, in accordance with current 
neurobiological hypotheses that implicate dysregulation of signal-transduction pathways, such as those 
regulated by calcineurin, in the etiology of affective disorders.
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Background
Calcineurin (CN; also known as Ca2+/protein phos-
phatase 2B) is a neuron enriched calcium/calmodulin
stimulated serine/threonine phosphatase composed of a
regulatory subunit (CNB) and a catalytic subunit (CNA).
There are three mammalian calcineurin catalytic isoforms
(CNA α, β and γ) and two regulatory isoforms (CNB1 and
CNB2). Acting as calcium-sensor, calcium-G protein sign-
aling integrator, and regulator of calcium homeostasis,
calcineurin shapes calcium and cyclic AMP dependent
processes: synaptic activity, receptor desensitization, cell
survival, neuroplasticity, cellular resilience [1]. Cal-
cineurin activation, overall, opposes cyclic AMP/PKA
actions, and the fine-tuning of this kinase/phosphatase
balance is critical for neuronal adaptation, transition to
long-term responses and higher functions including sen-
sitivity to aversive stimuli, fear conditioning, and impor-
tantly learning and memory [1].
Recently, different lines of evidence have suggested that
calcineurin could be a possible risk factor of schizophre-
nia. Most importantly, Gerber and collaborators [2]
reported the association of schizophrenia with genetic
variation of the PPP3CC gene, which encodes the CNA-γ-
subunit in a Caucasian population. The PPP3CC catalytic
subunit of calcineurin is located at 8p21, a highly repli-
cated schizophrenia susceptibility locus, and variants
within the gene are associated with schizophrenia. This
association is not seen in a Japanese sample [3]. However,
studies with transgenic animal models [4,5] show that
forebrain specific CNB knockout mice display behavioral
abnormalities reminiscent of both schizophrenia, such as
increased locomotion, decreased social interaction and
deficits in working memory and sensorimotor gating. In
addition pharmacological [6,7] studies in animals, as well
as post-mortem findings in schizophrenic patients [[8]
but see [9]] show that expression of calcineurin is altered
upon treatment with anti-psychotics and expression of the
PPP3CC and other calcineurin subunits is decreased in
the hippocampus of schizophrenic patients further impli-
cating calcineurin in neuropsychiatric disorders, such as
schizophrenia [10].
Alterations in calcineurin signaling may also be involved
in bipolar affective disorder (BPAD). Many of the pheno-
types of the CNB knock out mouse are also relevant to
BPAD, calcineurin subunits are down-regulated in the pre-
frontal cortex of BPAD patients and other genes involved
in calcineurin signaling, DARPP-32 (dopamine and cyclic
AMP regulated phosphoprotein of Mr 32,000), CDK5
(cyclin dependent kinase5), GSK3 (glycogen kinase syt-
nthase 3) and the calcineurin activated adenylyl cyclase 9,
have been associated with BPAD [11,12]. Finally, 8p21
has also been identified as a highly significant susceptibil-
ity locus for a psychotic form of BPAD [13].
Methods
We hypothesized that variants in the PPP3CC catalytic
subunit might also predispose to BPAD. We investigated
the association between PPP3CC and bipolar-affective-
disorder (BPAD) in a Caucasian French population of 115
BPAD patients and 97 healthy controls. BPAD patients
were recruited at two French University-affiliated Psychi-
atric Departments (one in Paris and one in Bordeaux).
Inclusion criteria comprised: BPAD I or II diagnosis
(according to DSM-IV criteria); Caucasian origin with at
least three out of four grandparents being French; being at
least 18 years old; being euthymic (having a MADRS
(Montgomery-Asberg Depressive Rating Scale) score of fif-
teen or less and a MAS (Bech and Raphaelsen Mania Rat-
ing Scale) score of five or less) at inclusion. The control
group comprised randomly selected blood donors having
no personal or family history of any psychiatric disorder.
Written informed consent was obtained from all partici-
pants. A trained psychiatrist using the French version of
the Diagnostic Interview for Genetic Studies (DIGS) pro-
viding lifetime DSM-IV axis I diagnoses interviewed
patients and control subjects. Male/female ratio was 0.72
in BPAD patients and 1.68 in controls. Based on the
PPP3CC/schizophrenia association study [2], we geno-
typed the two intronic single-nucleotide polymorphisms
(SNPs) showing strongest evidence for linkage (CC33T/C
and CCS3A/G). We also genotyped the coding sequence
mutation identified [2] on PPP3CC exon 5, resulting in a
nonconservative change in the amino acid sequence of the
protein from a charged arginine at position 163 to a neu-
tral glutamine (CC-5).
Results and discussion
We identified the CC-5 mutation in 3 patients and in 0
controls, a frequency comparable to that of the PPP3CC/
schizophrenia study (i.e. 3 of 210 tested patients and 0 of
75 Caucasian controls; [2]). For CC33 and CCS3, Hardy-
Weinberg-equilibrium was tested separately in cases and
controls. We also estimated linkage disequilibrium values
D' and r2 [14,15]. We tested for disease-haplotype associ-
ation by likelihood-based approaches using the EH-plus
software [16]. No deviation from Hardy-Weinberg-equi-
librium was observed for CC33 and CCS3, in both groups.
Association between BPAD and CC33 genotype was bor-
derline significant (p = 0.07), with an higher risk to
develop bipolar disorder for 'CT' or 'TT' carriers versus
'CC' carriers (OR = 1.8 [1.01–3.0]; p = 0.05) and a signif-
icant allelic association was observed with the 'T'-allele of
CC33 (p = 0.05, see Table 1 for details). Our results show
also a significant association between BPAD and CCS3 (p
= 0.003), with an higher risk to develop bipolar disorder
for 'AG' or 'GG' carriers versus 'AA' carriers (OR = 2.8 [1.5–
5.2]) and a significant allelic association between the 'G'-
allele of CCS3 and BPAD was observed (p = 0.002, see
table 1 for details). The CC33 and CCS3 polymorphismsBehavioral and Brain Functions 2008, 4:2 http://www.behavioralandbrainfunctions.com/content/4/1/2
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were observed in significant linkage disequilibrium (D' =
0.91, r2 = 0.72). Haplotype frequencies were significantly
different in BPAD patients than in controls (Likelihood
ratio test: Chi2 (3 ddf) = 9.08, p = 0.03), and a significant
over-transmission of the PPP3CC haplotype 'TG' (p =
0.001) was observed for bipolar patients. HapMap LD
data for the PPP3CC gene support the association being
due to a variant in PPP3CC and not a nearby gene.
In order to test an association between psychotic symp-
toms and PPP3CC polymorphisms, we have compared
genotypic repartition in psychotic (N = 59) versus non-
psychotic (N = 56) patients for both CC33 and CCS3 pol-
ymorphism. No difference was observed. Moreover, psy-
chotic and non-psychotic patient samples shown similar
association when compared to controls, suggesting that
these variants are implicated in bipolar disorder per se
and are not specific of psychotic symptoms.
As male/female ratio was significantly different between
patients and controls, we have performed genotypic and
haplotypic analyses stratified on gender. Similar results
were observed: a higher risk to develop bipolar disorder
for 'CT' or 'TT' carriers for CC33: OR = 1.45 [0.67–3.15]
for males and females OR = 2.54 [1.10–5.91]; association
between bipolar disorder and CC33 being significant only
for females (p = 0.03). For CCS3 polymorphism, 'AG' or
'GG' carriers have a higher risk than 'AA' carriers to
develop disease, (males OR = 1.29 [0.92–1.83] and
females OR = 2.57 [1.57–4.21]). However, association
between bipolar disorder and CC33 is significant only for
females (p < 0.001). Also association of CC33 haplotypes
was significant in females (Chi2 (3 df) = 50.6; p < 0.001)
and not significant in males (Chi2 (3 df) = 4.4; p = 0.22).
An over transmission of 'TG' haplotype was observed for
bipolar males and female patients.
Our results suggest that the PPP3CC gene may contribute
to the etiology of BPAD. This is in accordance with pre-
clinical work that relates calcineurin related signaling
pathways to the pathophysiology of affective and cogni-
tive disorders. Specifically it was shown that phosphatase
activity/amount could predict whether a signaling system
will operate in a proportional-response-mode, or as an
all-or-none-switch [17] susceptible to generate dispropor-
tional network responses. This might be relevant to the
bidirectional behavioral dysfunction (depressed or agi-
tated mood) characterizing BPAD. Furthermore, as stated
above, preclinical studies have implicated calcineurin in
cognitive function as well as in affective responsiveness
[1,5,18]. Our present findings suggest that PPP3CC might
be a shared susceptibility gene for schizophrenia and
BPAD. Calcineurin dysregulation, therefore, might be
associated with transnosographic phenotypical aspects,
such as affective and cognitive pathology, seen in both
disorders.
Table 1: Genotypic, Allelic and Haplotype association study of PPP3CC -CC33 and -CCS3 polymorphisms
Allele Count Cases Controls OR [CI_95%] p-value
CC33 CC 39 46 (CT+TT) versus CC 1.8 [1.01–3.0] 0.05
CT 52 36
TT 24 15
f(C) 0.57 0.66 -
f(T) 0.43 0.34 1.5 [1.01–2.2] 0.05
CCS3 Allele frequencies Cases Controls OR [CI_95%] p-value
AA 22 39 (GG+AG) vs AA 2.8 [1.5–5.2] 0.001
AG 60 41
GG 27 14
f(A) 0.48 0.63 -
f(G) 0.52 0.37 1.9 [1.3–2.8] 0.002
CC33/CCS3 Haplotype frequencies Cases Controls Chi-Square p-value
CA 0.47 0.61 TG versus (C2+CG+TA) 16.2 0.001
CG 0.09 0.05
TA - 0.02
TG 0.44 0.32Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
Behavioral and Brain Functions 2008, 4:2 http://www.behavioralandbrainfunctions.com/content/4/1/2
Page 4 of 4
(page number not for citation purposes)
Conclusion
We suggest that the PPP3CC gene might be a susceptibility
gene for BPAD, in accordance with the current neurobio-
logical hypothesis that implicates dysregulation of signal-
transduction pathways, such as those regulated by cal-
cineurin, in the etiology of affective disorders. We would
like however to point out some limitations related to our
approach. One must be aware that case/control associa-
tion studies often lead to non-replicable results. In this
respect our population is very small and ethnographic
bias cannot be excluded. In conclusion this is a case/con-
trol report with limited power that reports for the first
time an association between calcineurin and BPAD. Fur-
ther investigations with larger samples are warranted to
confirm this result.
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